NSE · THEMISMED · Pharmaceuticals
Themis Medicare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹77 Cr with net profit ₹2 Cr — a 2.57% net margin, versus 5.08% the period before.
Shareholding
As of 2026-06-30
- Promoter67.11%
- Public32.87%
- FII0.01%
- DII0.01%
21,267 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.28× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #52 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,960 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Themis Medicare Ltd.(this company) | ₹988 Cr | 111.75 | 2.71 | 0.42% | 0.33% |
AI analysis
AI-generated · google/gemini-2.5-flashThemis Medicare Ltd. (THEMISMED) has a market capitalization of Rs 1043 Cr. The company reported a revenue of Rs 410.18 Cr and a profit margin of 33.3%. Its earnings per share (EPS) stands at Rs 0.18.
Positives
- +The dividend yield is 44%, which is high.
- +Return on equity (ROE) is 41.6%, indicating efficient use of shareholder funds.
- +The debt-to-equity ratio is low at 0.25.
- +Promoter holding is 67.1052%, indicating a significant stake by the founders.
Negatives
- −The Price-to-Earnings (P/E) ratio is high at 628.94.
- −Return on Capital Employed (ROCE) is low at 2.7036%.
- −Net profit declined from Rs 10.09 Cr in Dec 2025 to Rs 8.89 Cr in Mar 2026.
- −Quarterly revenue decreased from Rs 90.13 Cr in Dec 2025 to Rs 76.53 Cr in Mar 2026.
- −Promoter pledge stands at 2.43% as of March 2026.
Financial Performance
Themis Medicare Ltd. reported revenue of Rs 410.18 Cr with a revenue growth of 6.2%. The net profit for the annual period ending March 2025 was Rs 29.833 Cr. However, recent quarterly performance shows a decline, with net profit falling to Rs 8.89 Cr in March 2026 from Rs 10.09 Cr in December 2025.
Profitability & Returns
The company’s profit margin is 33.3%. Return on equity (ROE) is reported at 41.6%, while return on capital employed (ROCE) is 2.7036%. Earnings per share (EPS) for the latest period stands at Rs 0.18.
Balance Sheet
The debt-to-equity ratio is 0.25. The book value per share is Rs 39.7. There has been a significant change in the dividend yield, which is currently at 44%.
Ownership & Pledges
As of March 31, 2026, promoter holding is 67.1052%. Public shareholding is 32.7752%, while institutional holding (DII and FII combined) is 0.1196%. There is a promoter pledge of 2.43% of total promoter holding, corresponding to 1,500,000 shares held by Vividhmargi Investments Pvt. Ltd. with a 6.14% holding.
Recent Quarterly Performance
The company's quarterly revenue decreased from Rs 90.13 Cr in Dec 2025 to Rs 76.53 Cr in Mar 2026. Net profit also declined from Rs 10.09 Cr in Dec 2025 to Rs 8.89 Cr in Mar 2026. The EBITDA decreased from Rs 8.49 Cr to Rs 4.83 Cr in the same period.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.